Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
James Buteau, Louise Kostos, Price Jackson, Lachlan McIntosh, Ramin Alipour, Timothy Akhurst, Michal Eifer, Brittany Emmerson, Mohammad B. Haskali, Kerry Jewell, Raghava Kashyap, Grace Kong, Declan G. Murphy, Aravind S. Ravi Kumar, Javad Saghebi, Shahneen Sandhu, Ben Tran, Jing Xie, Arun Azad, Michael S. Hofman (2025). First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5010.
Article146 days agoPrognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
Raghava Kashyap, James Buteau, Mathias Bressel, Michal Eifer, Neeraja Bollampally, Price Jackson, Lachlan McIntosh, Shahneen Sandhu, Michael S. Hofman (2025). Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. , DOI: https://doi.org/10.2967/jnumed.125.269640.
Article146 days agoPrognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
Raghava Kashyap, James Buteau, Mathias Bressel, Michal Eifer, Neeraja Bollampally, Price Jackson, Lachlan McIntosh, Shahneen Sandhu, Michael S. Hofman (2025). Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. , DOI: https://doi.org/10.2967/jnumed.125.269640.
Article146 days agoFirst-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
James Buteau, Louise Kostos, Price Jackson, Jing Xie, Mohammad B. Haskali, Ramin Alipour, Lachlan E McIntosh, Brittany Emmerson, Lisa L. MacFarlane, Claire A Martin, Joanna Chan, Sarah E. Williams, Kerry Jewell, Michal Eifer, A. Hamilton, W HARRIS, Tim Akhurst, Lewis Au, Anthony Cardin, Luc Furic, Raghava Kashyap, Grace Kong, Aravind S. Ravi Kumar, Declan G. Murphy, Rajeev Ravi, Javad Saghebi, Shahneen Sandhu, Ben Tran, Arun Azad, Michael S. Hofman (2025). First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study. , DOI: https://doi.org/10.1016/s1470-2045(25)00332-8.
Article146 days agoSafety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review
Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James Buteau, Declan G. Murphy, B.D. Kelly, Lavinia Spain, Shahneen Sandhu, Arun Azad, Elizabeth Medhurst, Grace Kong, Michael S. Hofman (2023). Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review. , 15, DOI: https://doi.org/10.1177/17588359231177018.
Article146 days ago